Current opinion in hematology · 2025
Cellular contributions to the pathogenesis of anti-platelet factor 4 disorders.
СтатьяОбзорПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Treverton Jared, Lychacz Mark, Arnold Donald M, Nazy Ishac
Аннотация
PURPOSE OF REVIEW: Anti-platelet factor 4 (PF4) disorders, including heparin-induced thrombocytopenia (HIT) and vaccine-induced immune thrombocytopenia and thrombosis (VITT), and emerging disorders such as VITT-like monoclonal gammopathy of thrombotic significance (MGTS), are monoclonal antibody-mediated and characterized by thrombocytopenia and thrombosis. Understanding the cellular and molecular mechanisms among these anti-PF4 disorders can help explain the variability in clinical presentations.
RECENT FINDINGS: Recent work demonstrated that beyond platelets, immune and vascular cells serve a critical role in driving thrombosis and the severity of clinical outcomes. Neutrophils drive thrombosis via NETosis, monocytes release tissue factor-rich microparticles, and endothelial cells provide adhesive and immunogenic surfaces that sustain thromboinflammation. Thus, our understanding of the pathogenesis of anti-PF4 disorders is defined by complex interactions and effector functions of multiple cellular contributors working in parallel to create a highly prothrombotic environment.
SUMMARY: A deeper understanding of these intercellular pathways will shed light on the role of innate immune cells, in addition to platelets, in creating variable clinical outcomes between anti-PF4 disorders and reveal novel therapeutic targets. This expands our understanding of unifying mechanisms between these disorders and informs future strategies to improve diagnosis and treatment.
RECENT FINDINGS: Recent work demonstrated that beyond platelets, immune and vascular cells serve a critical role in driving thrombosis and the severity of clinical outcomes. Neutrophils drive thrombosis via NETosis, monocytes release tissue factor-rich microparticles, and endothelial cells provide adhesive and immunogenic surfaces that sustain thromboinflammation. Thus, our understanding of the pathogenesis of anti-PF4 disorders is defined by complex interactions and effector functions of multiple cellular contributors working in parallel to create a highly prothrombotic environment.
SUMMARY: A deeper understanding of these intercellular pathways will shed light on the role of innate immune cells, in addition to platelets, in creating variable clinical outcomes between anti-PF4 disorders and reveal novel therapeutic targets. This expands our understanding of unifying mechanisms between these disorders and informs future strategies to improve diagnosis and treatment.